がんの浸潤と転移のシグナルネットワークを探る

過程はtgf-βの働きを抑えるようなタンパク質や薬剤を投与することで抑制でき、マウスを使った実 験モデルではemt を抑えることで乳がんの肝臓への転移を抑制できることを発見しました。

Breast Cancer Facts & Figures 2017-2018

are further defined by being highly positive for Ki67 (indicator of a large proportion of actively dividing cells) or HER2. Luminal B breast cancers tend to be higher grade and are associated with poorer survival than luminal A cancers.13 • HER2-enriched (HR-/HER2+) (5%). HER2-enriched cancers tend to grow and spread more aggressively

  Positive, Her2

Lynparza Full Prescribing Information

m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients

  Information, Prescribing, Full, Positive, Full prescribing information, Her2

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Verzenios is indicated for the treatment of women with hormone receptor (HR) -positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy , or in women who have received prior endocrine therapy.

  Product, Summary, Positive, Characteristics, Summary of product characteristics, Her2